CNS Pharmaceuticals, Inc. - Common Stock Share · US18978H2013 · CNSP (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of CNS Pharmaceuticals, Inc. - Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

01.05.2026 20:00

Current Prices from CNS Pharmaceuticals, Inc. - Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	CNSP	USD	01.05.2026 20:00	2,31 USD	0,04 USD +1,81 %
IEX	CNSP	USD	22.04.2026 19:34	2,31 USD	-

Share Float & Liquidity

Free Float 107,95 %

Shares Float 620.280,00

Shares Outstanding 574.580,00

Company Profile for CNS Pharmaceuticals, Inc. - Common Stock Share

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.